The completion of the first procedure marks the beginning of a controlled US commercial release.
|Videos|June 25, 2021
Dr. Eure on clinical use and reimbursement of UroLift for BPH
Author(s)Urology Times staff
Advertisement
Gregg Eure, MD, FACS, Urology of Virginia, discusses the UroLift System as an early, noninvasive treatment option for patients with BPH. He also addresses reimbursement of the treatment.
Advertisement
Related to this article
Butterfly Medical has also submitted a premarket approval application to the FDA.
Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.
Advertisement
Advertisement
Trending on Urology Times
1
How PSMA-PET shapes staging and recurrence workup in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
4
Engy Habashy, MD, on the role of androgens in GSM management
5